| pubmed-article:1353693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1353693 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1353693 | lifeskim:mentions | umls-concept:C0007095 | lld:lifeskim |
| pubmed-article:1353693 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:1353693 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:1353693 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1353693 | pubmed:dateCreated | 1992-9-10 | lld:pubmed |
| pubmed-article:1353693 | pubmed:abstractText | The action of IFN-alpha has been studied in patients with carcinoid tumours. More than 300 patients have been treated with IFN-alpha for long periods of time (median 2.5 years). IFN-alpha exerts many pleiotrophic effects in carcinoid tumours. Antiproliferative effects are manifest mainly by a cell cycle block in GO-G1 phase and prolongation of the S-phase. Hormone synthesis is impaired with reduced circulating hormone levels after IFN-alpha therapy and the mechanism includes reduction of mRNA expression for various hormones. Induction in vitro of the nuclear enzyme 2'-5-A synthetase in tumour cells correlates with biochemical response and might account for reduced mRNA expression. IFN-alpha induces significantly increased intratumoral fibrosis in carcinoid metastases without significant changes in tumour size. Finally IFN-alpha causes alteration of the major histocompatibility complex (MHC) with increased expression of class I antigens on the tumour cells. The net result of all these effects of IFN-alpha is an antitumour effect in 70-80% of carcinoid tumour patients with biochemical control and abrogated tumour growth for extended periods of time. However, when IFN-alpha therapy is withdrawn tumour progression occurs within 3-9 months, indicating a controlling but not curing effect. | lld:pubmed |
| pubmed-article:1353693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1353693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1353693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1353693 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:1353693 | pubmed:issn | 1044-579X | lld:pubmed |
| pubmed-article:1353693 | pubmed:author | pubmed-author:ObergKK | lld:pubmed |
| pubmed-article:1353693 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1353693 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:1353693 | pubmed:geneSymbol | neu | lld:pubmed |
| pubmed-article:1353693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1353693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1353693 | pubmed:pagination | 35-41 | lld:pubmed |
| pubmed-article:1353693 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:meshHeading | pubmed-meshheading:1353693-... | lld:pubmed |
| pubmed-article:1353693 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1353693 | pubmed:articleTitle | The action of interferon alpha on human carcinoid tumours. | lld:pubmed |
| pubmed-article:1353693 | pubmed:affiliation | Department of Internal Medicine, University Hospital, Uppsala, Sweden. | lld:pubmed |
| pubmed-article:1353693 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1353693 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1353693 | lld:pubmed |
